Claims for Patent: 6,927,044

Summary for Patent: 6,927,044

Title:	IL-1 receptor based cytokine traps
Abstract:	Fusion polypeptides capable of binding interleukin-1 (IL-1) to form a nonfunctional complex are provided and nucleic acid molecules encoding the fusion polypeptides. The fusion ploypeptides form dimers to function as IL-1 antagonists.
Inventor(s):	Stahl; Neil (Carmel, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	10/282,162
Patent Claims:	1. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:33. 2. A fusion polypeptide encoded by the nucleic acid molecule of claim 1. 3. The nucleic acid molecule of claim 1, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:34. 4. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:35. 5. A fusion polypeptide encoded by the nucleic acid molecule of claim 4. 6. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:36. 7. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:37. 8. A fusion polypeptide encoded by the nucleic acid molecule of claim 7. 9. The A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:38. 10. The nucleic acid of claim 1, 4, or 7, wherein nucleotide 1979 is changed from A to C. 11. A fusion polypeptide encoded by the nucleic acid molecule of claim 10. 12. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:39. 13. A fusion polypeptide encoded by the nucleic acid molecule of claim 12. 14. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:40. 15. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:41. 16. A fusion polypeptide encoded by the nucleic acid molecule of claim 15. 17. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:42. 18. A recombinant nucleic acid molecule encoding a fusion polypeptide which forms a multimer capable of binding interleukin-1 (IL-1) to form a nonfunctional complex, wherein the nucleic acid molecule comprises SEQ ID NO:43. 19. A fusion polypeptide encoded by the nucleic acid molecule of claim 18. 20. A nucleic acid molecule encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:44. 21. The nucleic acid of claim 12, 15, or 18, wherein nucleotide 1043 is changed from A to C. 22. A fusion polypeptide encoded by the nucleic acid molecule of claim 21. 23. A composition capable of binding IL-1 to form a non-functional complex comprising a multimer of the fusion polypeptide of any of claims 2, 5, 8, 11, 13, 16, 19, or 22. 24. The composition of claim 23, wherein the multimer is a dimer. 25. A vector comprising the nucleic acid molecule of any of claims 1, 4, 7, 10, 12, 15, 18, and 21. 26. An expression vector comprising the nucleic acid molecule of any of claims 1, 4, 7, 10, 12, 15, 18, and 21 operatively linked to an expression control sequence. 27. A host-vector system for the production of a fusion polypeptide, comprising the expression vector of claim 26 in a suitable host cell. 28. The host-vector system of claim 27, wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell. 29. A method of producing a fusion polypeptide that comprises growing cells of the host-vector system of claim 27, under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced. 30. The host-vector system of claim 28, wherein the suitable host cell is a CHO cell.

Details for Patent 6,927,044

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	02/27/2008		2018-09-25

International Patent Family for US Patent 6,927,044

Country	Patent Number	Estimated Expiration
Austria	283365
Austria	336583
Austria	420970